image:
(A, B, C) Comparison of the cumulative incidence of three events among patients with various levels of HBV DNA. (D, E, F) Comparison of the cumulative incidence of three events in three subgroups of patients with HBV DNA ≥ 2,000 IU/mL. ***p<0.001; *p<0.0167; nanoseconds, p>0.05. BL, baseline; HCC, hepatocellular carcinoma.
view more
Image source: Jing Zhou and En-Qiang Chen
The study delves into a traditionally overlooked category of patients with chronic hepatitis B. Although those who are HBeAg negative but have normal ALT levels are considered low risk and are often excluded from immediate treatment, this study challenges this view by demonstrating the substantial benefit of continued antiviral therapy. This study conducted a retrospective analysis of 194 patients diagnosed with HBeAg-negative chronic hepatitis B over a median period of 54 months. Hepatitis B virus (HBV) DNA was detected in these patients and they were classified according to treatment regimen: continuous, intermittent, or no nucleos
Magazine
Journal of Clinical and Translational Hepatology
research topic
people
Article title
Antiviral therapy can help reduce the risk of cirrhosis in HBeAg-negative chronic hepatitis B patients with normal alanine aminotransferase and positive HBV DNA
Article publication date
August 25, 2023
Disclaimer: The American Association for the Advancement of Science (AAAS) and EurekAlert! are not responsible for the accuracy of press releases posted to EurekAlert! Organizations that contribute or use any information through the EurekAlert system.